To promptly recognize and manage cardiovascular (CV) risk factors before, during, and after cancer treatment, decreasing the risk of cancer therapy–related cardiac dysfunction is crucial. After recent advances in breast cancer treatment, mortality rates from cancer have decreased, and the prevalence of survivors with a potentially higher CV disease risk has increased. Cardiovascular risks might be associated with the multimodal approach, including systemic therapies and breast radiotherapy (RT).
The heart disease risk seems to be higher in patients with tumors in the left breast, when other classic CV risk factors are present, and when adjunctive anthracycline-based chemotherapy is administered, suggesting a synergistic association. Respiratory control as well as modern RT techniques and their possible further refinement may decrease the prevalence and severity of radiation-induced heart disease. Several pharmacological cardioprevention strategies for decreasing cardiac toxic effects have been identified in several guidelines. However, further research is needed to ascertain the feasibility of these strategies in routine practice.
Conclusions and Relevance
This review found that evidence-based recommendations are lacking on the modalities for and intensity of heart disease screening, surveillance of patients after RT, and treatment of these patients. A multidisciplinary and multimodal approach is crucial to guide optimal management.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: September 29, 2020.
Published Online: March 4, 2021. doi:10.1001/jamaoncol.2020.7468
Corresponding Author: Icro Meattini, MD, Department of Experimental and Clinical Biomedical Sciences Mario Serio, University of Florence, Viale Morgagni 50, 50134 Florence, Italy (firstname.lastname@example.org).
Author Contributions: Dr Meattini had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Meattini and Poortmans contributed equally to the work.
Concept and design: Meattini, Poortmans, Cardinale, Lenihan, Marrazzo, Curigliano, Livi.
Acquisition, analysis, or interpretation of data: Meattini, Poortmans, Aznar, Becherini, Bonzano, Curigliano.
Drafting of the manuscript: Meattini, Poortmans, Aznar, Becherini, Bonzano, Cardinale, Marrazzo, Curigliano.
Critical revision of the manuscript for important intellectual content: Meattini, Poortmans, Aznar, Becherini, Cardinale, Lenihan, Marrazzo, Curigliano, Livi.
Administrative, technical, or material support: Meattini, Poortmans, Aznar, Becherini, Curigliano.
Supervision: Meattini, Poortmans, Cardinale, Lenihan, Curigliano, Livi.
Other - bibliographic research and manuscript writing, figures and tables: Marrazzo.
Conflict of Interest Disclosures: Dr Meattini reported serving on the advisory boards of Lilly, Pfizer, Roche, and Novartis outside the submitted work. Dr Poortmans reported being a medical advisor for Sordina IORT Technologies SpA. Dr Aznar reported receiving grants from the National Institute for Health Research Manchester Biomedical Research Centre and from the Cancer Research UK RadNet Manchester during the conduct of the study. Dr Lenihan reported receiving grants from Myocardial Solutions Inc outside the submitted work. Dr Marrazzo reported receiving financial support from Elekta to participate in the European Society for Radiotherapy and Oncology Congress. Dr Curigliano reported receiving grants from Merck and other from Roche, Novartis, Daiichi Sankyo, AstraZeneca, Lilly, Pfizer, Merck, BMS, and Ellipsis outside the submitted work. No other disclosures were reported.
Additional Contributions: Katherine Jones, MSc, The Christie NHS Foundation Trust; Giorgio Cartechini, MSc, University of Trento; and Marco Schwarz, MSc, PhD, Proton Therapy Center, provided permission to reprint the images in figures 2 and 3. These individuals received no additional compensation, outside of their usual salary, for their contributions.
Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:
It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.
You currently have no searches saved.
You currently have no courses saved.